DR. THOMAS WAYNE BRUICE, M.D., PH.D.
Medical Practice at Palermi Pl, Carlsbad, CA

6610663, Aug 26, 2003

Oct 10, 2001

09/974326

Phillip Dan Cook - Carlsbad CA
Thomas Bruice - Carlsbad CA
Charles John Guinosso - Vista CA
Andrew Mamoru Kawasaki - Oceanside CA
Richard Griffey - San Marcos CA

ISIS Pharmaceuticals, Inc. - Carlsbad CA

A61K 4800

514 44, 536 231, 536 245, 536221, 435 6

Compositions and methods for modulating the activity of RNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. The reactive portions preferably comprise one or two imidazole functionalities conjugated to the targeting oligonucleotide via linkers with or without intervening intercalating moieties. Therapeutics, diagnostics and research methods also are disclosed, as are synthetic nucleosides and nucleoside fragments that can be elaborated into oligonucleotides.

6423489, Jul 23, 2002

May 30, 1995

08/452841

Kevin P. Anderson - Carlsbad CA
Ronnie C. Hanecak - San Clemente CA
Kazuya Hoshiko - Kumamoto, JP
Chikateru Nozaki - Kumamoto, JP
Tsukasa Nishihara - Kumamoto, JP
Hiroshi Nakatake - Kikuyo-machi, JP
Fukusaburo Hamada - Nishigoshi-machi, JP
Tatsuo Eto - Ohzu-machi, JP
Shinichi Furukawa - Koshi-machi, JP
Shoji Furusako - Tokyo, JP
Thomas W. Bruice - Carlsbad CA
Walter F. Lima - San Diego CA

Isis Pharmaceuticals, Inc. - Carlsbad CA

C12Q 168

435 6, 435325, 435366, 536 231, 536 245

Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.

6368863, Apr 9, 2002

Feb 23, 1999

09/255899

David J. Ecker - Carlsbad CA
Thomas W. Bruice - Carlsbad CA
Timothy Vickers - Vista CA

ISIS Pharmaceuticals Inc. - Carlsbad CA

C12N 1511

435455, 435325, 435366, 435375, 435 5, 435 6, 435 71, 536 231, 536 241, 536 245

Methods for modulating expression of a gene are provided. The methods comprise the steps of selecting a portion of an RNA coded by the gene, wherein the RNA is capable of interacting with a protein, preparing an oligonucleotide or oligonucleotide analog to mimic the portion of the RNA, and contacting cells containing the gene with the oligonucleotide or oligonucleotide analog. Methods of treating a disease are also provided. The methods comprise selecting a portion of an RNA coded by a gene whose expression is believed to be responsible for the disease, preparing an oligonucleotide or oligonucleotide analog to mimic the portion, and contacting an organism suspected of having the disease with the oligonucleotide or oligonucleotide analog.

6391542, May 21, 2002

May 17, 1996

08/650093

Kevin P. Anderson - Carlsbad CA
Ronnie C. Hanecak - San Clemente CA
Kazuya Hoshiko - Kumamoto, JP
Chikateru Nozaki - Kumamoto, JP
Tsukasa Nishihara - Kumamoto, JP
Hiroshi Nakatake - Kikuyo-machi, JP
Fukusaburo Hamada - Nishigoshi-machi, JP
Tatsuo Eto - Ohzu-machi, JP
Shinichi Furukawa - Koshi-machi, JP
Shoji Furasako - Tokyo, JP
Thomas W. Bruice - Carlsbad CA
Walter F. Lima - San Diego CA

Isis Pharmaceuticals, Inc. - Carlsbad CA

C12Q 168

435 6, 435 911, 435325, 435375, 536 231, 536 245

Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.

5672472, Sep 30, 1997

Feb 22, 1994

8/196103

David J. Ecker - Leucadia CA
Jacqueline Wyatt - Carlsbad CA
Thomas W. Bruice - Carlsbad CA
Kevin Anderson - Carlsbad CA
Ronnie C. Hanecak - San Clemente CA
Timothy Vickers - Oceanside CA
Peter Davis - Carlsbad CA

ISIS Pharmaceuticals, Inc. - Carlsbad CA

C12Q 170, C12Q 168, C07H 2100, C12P 1934

435 6

Methods useful for the determination of oligomers which have specific activity for a target molecule from a pool of primarily randomly assembled subunits are provided. The disclosed methods involve repeated syntheses of increasingly simplified sets of oligomers coupled with selection procedures for determining oligomers having the highest activity. Freedom from the use of enzymes allows the application of these methods to any molecules which can be oligomerized in a controlled fashion.

7807653, Oct 5, 2010

Jun 14, 2007

11/818666

Phillip D. Cook - Fallbrook CA, US
Guangyi Wang - Carlsbad CA, US
Thomas W. Bruice - Carlsbad CA, US
Nicholas A. Boyle - Encinitas CA, US
Janet M. Leeds - Encinitas CA, US
Jennifer L. Brooks - Encinitas CA, US
Marija Prhavc - Encinitas CA, US
Maria Eugenia Ariza - San Marcos CA, US
Patrick C. Fagan - Escondido CA, US
Yi Jin - Carlsbad CA, US
Vivek K. Rajwanshi - Vista CA, US
Kathleen D. Tucker - Escondido CA, US

Biota Scientific Management Pty Ltd - Notting Hill, Victoria

A61K 31/7076, A61K 31/708, C07H 19/20

514 47, 514 48, 536 276, 536 2761, 536 2762, 536 2763, 536 277, 536 278, 536 2781

The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.

7285658, Oct 23, 2007

Feb 28, 2003

10/376654

Phillip D. Cook - Fallbrook CA, US
Guangyi Wang - Carlsbad CA, US
Thomas W. Bruice - Carlsbad CA, US
Nicholas A. Boyle - Encinitas CA, US
Janet M. Leeds - Encinitas CA, US
Jennifer L. Brooks - Encinitas CA, US
Marija Prhavc - Encinitas CA, US
Maria Eugenia Ariza - San Marcos CA, US
Patrick C. Fagan - Escondido CA, US
Yi Jin - Carlsbad CA, US
Vivek K. Rajwanshi - Vista CA, US
Kathleen D. Tucker - Escondido CA, US

Biota, Inc. - Carlsbad CA

A61K 31/7072, A61K 31/7076, C07H 19/167, C07H 19/173, C07H 19/19, C07H 19/20

536 262, 536 2622, 536 2626, 514 49, 514 51

The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.

5866698, Feb 2, 1999

Apr 13, 1994

8/227180

David Ecker - Carlsbad CA
Timothy A. Vickers - Vista CA
Thomas W. Bruice - Carlsbad CA

Isis Pharmaceuticals, Inc. - Carlsbad CA

C07H 2102, C07H 2104

536 245

Methods for modulating the expression of viral genes are provided by selecting a portion of RNA coded by the gene, said RNA portion having subportions forming a secondary structure, and contacting the RNA with oligonucleotide of 6 to 50 which can bind with at least one of said subportions of the RNA. In accordance with the preferred embodiments, oligonucleotides are designed to bind to RNA secondary structures which are of significance to the expression of the gene coding for said RNA. In accordance with a preferred embodiment, methods of treatment of human immunodeficiency virus are similarly disclosed wherein the oligonucleotides are targeted at the CAR or gag-pol region of HIV RNA.

5543507, Aug 6, 1996

Mar 2, 1994

8/205507

Phillip D. Cook - Carlsbad CA
Muthiah Manoharan - Carlsbad CA
Thomas Bruice - Carlsbad CA

ISIS Pharmaceuticals, Inc. - Carlsbad CA

C07H 2100, C07H 2102, C07H 2104

536 231

Covalent cross-linkages for two oligonucleotide strands or for first and second regions of a single oligonucleotide strand connect sugar moieties of nucleotides on the respective strands or the regions of the single strand. The cross-linkages are connected to at least one strand or region via a space-spanning group. The cross-linkage also can be connected to the other strand or other region via a space-spanning group or via an abasic site located on the other strand or other region.

7189506, Mar 13, 2007

Mar 3, 2000

09/518297

Moon Young Lim - Redwood City CA, US
Cynthia A. Edwards - Morgan Hill CA, US
Kirk E. Fry - Palo Alto CA, US
Thomas W. Bruice - Carlsbad CA, US
Douglas B. Starr - Mountain View CA, US
Megan E. Laurance - San Francisco CA, US
Yan Kwok - Sunnyvale CA, US
Albert W. Tam - San Francisco CA, US

Genelabs Technologies, Inc. - Redwood City CA

C12Q 1/68, C07H 21/04

435 6, 435 721, 435 723, 435 691, 4352351, 436501, 536 231, 536 234, 536 235, 536 236, 536 237

The present invention provides molecular switch system methods and compositions for use in regulatable gene expression. The system includes a nucleic acid construct which has a DNA response sequence for a transcriptional regulatory protein operably linked to a promoter, a compound binding sequence in the vicinity of the DNA response sequence, a transgene under the control of the promoter; and a DNA binding compound. In some cases, the molecular switch system further includes a nucleic acid sequence encoding a transcriptional regulatory protein operably linked to a second promoter. The invention further provides a method for screening compounds for the ability to function in the molecular switch system and thereby regulate gene expression.